Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher Risk Myelodysplastic Syndrome: The Phase 3, Randomized, ENHANCE Study

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
Daver, Naval [1 ]
Xu, Jin [2 ]
Chao, Mark [2 ]
Chung, Trisha [2 ]
Tan, Anderson [2 ]
Wang, Yan [2 ]
Wei, Andrew [3 ,4 ]
Vyas, Paresh [5 ]
Sallman, David [6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[3] Alfred Hosp, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Univ Oxford, Oxford, England
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-1
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [1] Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Vivian
    Wei, Andrew
    Vyas, Paresh
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [3] Impact of Mutational Landscape and CD47 Levels in the Magrolimab plus Azacitidine Vs Placebo plus Azacitidine Trial in Patients with Untreated Higher Risk Myelodysplastic Syndrome
    Johnson, Lisa D. S.
    Zhang, Yajia
    BLOOD, 2024, 144 : 4604 - 4605
  • [4] A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
    Jacoby, Meagan A.
    Abboud, Camille N.
    Dipersio, John F.
    Cashen, Amanda F.
    Walter, Matthew J.
    Pizarro, Rigoberto De Jesus
    Uy, Geoffrey L.
    BLOOD, 2015, 126 (23)
  • [5] G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
    Tomáš Stopka
    Lubomír Minařík
    Nina Dusilková
    Michal Pešta
    Vojtěch Kulvait
    Martin Špaček
    Zuzana Zemanová
    Marta Kalousová
    Anna Jonášová
    Blood Cancer Journal, 12
  • [6] G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
    Stopka, Tomas
    Minarik, Lubomir
    Dusilkova, Nina
    Pesta, Michal
    Kulvait, Vojtech
    Spacek, Martin
    Zemanova, Zuzana
    Kalousova, Marta
    Jonasova, Anna
    BLOOD CANCER JOURNAL, 2022, 12 (07)
  • [7] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [8] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Sekeres, Mikkael A.
    Watts, Justin
    Radinoff, Atanas
    Sangerman, Montserrat Arnan
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua F.
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Ades, Lionel
    LEUKEMIA, 2021, 35 (07) : 2119 - 2124
  • [9] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 2119 - 2124
  • [10] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Breems, Dimitri
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ching, Keith
    O'Brien, Thomas
    Stampino, Corrado Gallo
    Ma, Weidong Wendy
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
12345